[go: up one dir, main page]

IN2015DN00976A - - Google Patents

Info

Publication number
IN2015DN00976A
IN2015DN00976A IN976DEN2015A IN2015DN00976A IN 2015DN00976 A IN2015DN00976 A IN 2015DN00976A IN 976DEN2015 A IN976DEN2015 A IN 976DEN2015A IN 2015DN00976 A IN2015DN00976 A IN 2015DN00976A
Authority
IN
India
Prior art keywords
epcs
pah
treated
treating
prostacyclin
Prior art date
Application number
Inventor
Roger Jeffs
Thomas Petersen
Roger M Ilagan
Michael Wade
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of IN2015DN00976A publication Critical patent/IN2015DN00976A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/041—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The current application is directed to a method for treating pulmonary arterial hypertension (PAH) comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
IN976DEN2015 2012-08-01 2013-07-30 IN2015DN00976A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678208P 2012-08-01 2012-08-01
US201361750458P 2013-01-09 2013-01-09
PCT/US2013/052700 WO2014022376A2 (en) 2012-08-01 2013-07-30 Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

Publications (1)

Publication Number Publication Date
IN2015DN00976A true IN2015DN00976A (en) 2015-06-12

Family

ID=50028652

Family Applications (1)

Application Number Title Priority Date Filing Date
IN976DEN2015 IN2015DN00976A (en) 2012-08-01 2013-07-30

Country Status (9)

Country Link
US (4) US10016463B2 (en)
EP (2) EP2879684B1 (en)
JP (2) JP6746313B2 (en)
KR (1) KR102143961B1 (en)
CN (1) CN104936603A (en)
CA (1) CA2880811C (en)
ES (2) ES2869701T3 (en)
IN (1) IN2015DN00976A (en)
WO (1) WO2014022376A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN00976A (en) * 2012-08-01 2015-06-12 United Therapeutics Corp
IN2015DN00934A (en) 2012-08-01 2015-06-12 United Therapeutics Corp
EP3878452B1 (en) * 2013-01-09 2023-09-20 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
EP3808731A1 (en) 2013-10-25 2021-04-21 Insmed Incorporated Prostacyclin compounds
CA2946747A1 (en) * 2014-04-23 2015-10-29 Texas Heart Institute Methods of enhancing stem cell engraftment
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
NZ746793A (en) 2016-04-07 2022-10-28 Proteostasis Therapeutics Inc Silicone atoms containing ivacaftor analogues
KR102606101B1 (en) * 2016-10-24 2023-11-27 유나이티드 쎄러퓨틱스 코포레이션 Enhancement of MSC immunomodulatory properties by treprostinil
KR20190109399A (en) * 2016-12-05 2019-09-25 코세어 파마 인코포레이티드 Dermal and Transdermal Administration of Treprostinil and Its Salts
CN113490412B (en) 2018-10-05 2023-07-28 药物治疗股份有限公司 Xenograft articles and methods
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
AU2020265576B2 (en) 2019-04-29 2025-09-18 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
EP3999030A4 (en) * 2019-07-15 2023-08-16 Yale University METHODS AND COMPOSITIONS FOR TREATING PULMONARY ARTERIAL HYPERTENSION
KR20220054359A (en) * 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 How to treat vascular disease

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5026365A (en) 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
ATE81724T1 (en) 1987-11-09 1992-11-15 Becton Dickinson Co PROCEDURE FOR ANALYZING HAEMATOPOIETIC CELLS IN A SAMPLE.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5071741A (en) 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
DE3829752A1 (en) 1988-09-01 1990-03-22 Akzo Gmbh INTEGRAL ASYMMETRICAL POLYAETHERSULPHONE MEMBRANE, METHOD FOR THE PRODUCTION AND USE FOR ULTRAFILTRATION AND MICROFILTRATION
DE3829766A1 (en) 1988-09-01 1990-03-22 Akzo Gmbh METHOD FOR PRODUCING MEMBRANES
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
EP0624190A4 (en) 1992-01-21 1995-04-19 Cryopharm Corp METHOD FOR FREEZING CELLS AND MATERIALS SIMILAR TO CELLS.
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
JP4098355B2 (en) 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド Biocompatible immunoisolation capsule containing genetically modified cells
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
JP3591837B2 (en) 1994-02-17 2004-11-24 ニューヨーク・ブラッド・センター・インコーポレイテッド Biological bioadhesive composition containing fibrin glue and liposomes, method of manufacture and use thereof
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5580714A (en) 1995-03-08 1996-12-03 Celox Laboratories, Inc. Cryopreservation solution
US5629145A (en) 1995-03-24 1997-05-13 Organ, Inc. Cryopreservation of cell suspensions
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
AU1333797A (en) 1995-12-15 1997-07-03 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
WO1998014058A1 (en) 1996-10-03 1998-04-09 The Regents Of The University Of California Cryopreservation of human adult and fetal pancreatic cells and human platelets
ATE307195T1 (en) 1997-07-14 2005-11-15 Osiris Therapeutics Inc CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US9585916B2 (en) * 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US9320829B2 (en) 2000-03-15 2016-04-26 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU7362301A (en) 2000-06-22 2002-01-02 Sam L Austin Bioadhesive compositions and methods of preparation and use
AU2003297592A1 (en) 2002-11-30 2004-06-23 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
CN1917866B (en) 2003-12-16 2010-12-15 联合治疗公司 Use of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment and prevention of ischemic lesions
EP2348105B1 (en) 2004-09-24 2018-10-24 Mesoblast, Inc. Multipotential expanded mesenchymal precursor cell progeny (MEMP) and uses thereof
WO2007022515A2 (en) 2005-08-19 2007-02-22 Duke University Stem cell derived factors for treating pathologic conditions
US20070065414A1 (en) 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
WO2007124594A1 (en) 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
US20100040584A1 (en) 2006-12-19 2010-02-18 Children's Medical Center Corporation Methods for promoting neovascularization
KR20150039214A (en) 2007-02-12 2015-04-09 안트로제네시스 코포레이션 Treatment of inflammatory diseases using placental stem cells
JP2011015609A (en) * 2007-10-30 2011-01-27 Asahikawa Medical College Method for induction of proliferation/differentiation of endothelial progenitor cell (epc)
HRP20150510T1 (en) 2008-02-22 2015-06-05 Agency For Science, Technology, And Research (A*Star) Mesenchymal stem cell particles
CA2842181C (en) 2010-08-27 2021-01-05 University Of Miami Bone marrow derived cd271 precursor cells for cardiac repair
DK2760994T4 (en) 2011-09-30 2021-10-11 Bluebird Bio Inc CONNECTIONS TO INCREASED VIRAL TRANSDUCTION
IN2015DN00934A (en) 2012-08-01 2015-06-12 United Therapeutics Corp
IN2015DN00976A (en) * 2012-08-01 2015-06-12 United Therapeutics Corp
EP3878452B1 (en) * 2013-01-09 2023-09-20 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US9924630B2 (en) 2014-11-14 2018-03-27 Luitauras Kairys Device for connecting two rakes
KR102606101B1 (en) 2016-10-24 2023-11-27 유나이티드 쎄러퓨틱스 코포레이션 Enhancement of MSC immunomodulatory properties by treprostinil

Also Published As

Publication number Publication date
ES2713988T3 (en) 2019-05-24
US10016463B2 (en) 2018-07-10
US20210030812A1 (en) 2021-02-04
US10842823B2 (en) 2020-11-24
JP6810717B2 (en) 2021-01-06
EP3492084B1 (en) 2021-02-17
ES2869701T3 (en) 2021-10-25
US12310992B2 (en) 2025-05-27
EP3492084A1 (en) 2019-06-05
US20150216909A1 (en) 2015-08-06
US11839631B2 (en) 2023-12-12
CA2880811A1 (en) 2014-02-06
KR102143961B1 (en) 2020-08-12
WO2014022376A2 (en) 2014-02-06
CA2880811C (en) 2021-12-07
JP6746313B2 (en) 2020-08-26
US20240131078A1 (en) 2024-04-25
JP2015524438A (en) 2015-08-24
EP2879684B1 (en) 2019-01-30
EP2879684A2 (en) 2015-06-10
US20180280445A1 (en) 2018-10-04
JP2018135352A (en) 2018-08-30
KR20150036716A (en) 2015-04-07
CN104936603A (en) 2015-09-23
WO2014022376A3 (en) 2015-07-16
EP2879684A4 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
IN2015DN00976A (en)
MY185016A (en) Progenitor cells of mesodermal lineage
GB2482536B (en) Expression of antibody or a fragment thereof in lactobacillus
IL237021B (en) Pharmaceutical composition for treatment of pulmonary arterial hypertension with mesenchymal stem cells
PH12013500760B1 (en) Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same
GB2483520B (en) Oxygen concentrator and method
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
GB201316021D0 (en) Vitamin D composition
WO2011083091A3 (en) Methods for treating pancreatic cancer
IN2014DN06104A (en)
EA201490614A1 (en) TREATMENT OF DISEASES AND DISTURBANCES CAUSED BY ACTIVITY OF NF-kB TRANSCRIPTION FACTOR
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MY161868A (en) Anti-bv8 antibodies and uses thereof
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
MX2013013685A (en) Method of treating articles with carbon dioxide.
GB201109238D0 (en) Antibodies
ZA201305234B (en) Process for the treatment and the winemaking of grapes
IN2014DN08385A (en)
MX2012010382A (en) Modulating aquaporins with relaxin.
WO2012020108A3 (en) Multimeric inhibitors of viral fusion and uses thereof
MX2015012580A (en) The use of sdf-1 to mitigate scar formation.
MX347541B (en) Sialic acid analogs.
WO2013074816A3 (en) Novel inhibitors of nox1
MX2013011919A (en) Variants of human gdnf.
UA57596U (en) “frankivska hostyna”, special vodka